Takeda's Ninlaro Available Under Managed Access In Europe
This article was originally published in Scrip
Clinigen Group PLC has initiated a managed access program for Ninlaro (ixazomib) for patients with multiple myeloma. The drug, developed by Takeda Pharmaceutical Co. Ltd., was approved by the US FDA earlier this month after receiving priority review status in September.
Register for our free email digests: